Helix BioPharma (HBP) AI Stock Analysis

• Market Cap: C$156.58M
• Dividend Yield: N/A
• Average Volume (3M): 13.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: N/A
• EPS Growth: 59.00%
• Country: CA
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 76,378,100
• 10 Day Avg. Volume: 29,165
• 30 Day Avg. Volume: 13,000
• PEG Ratio: 0.21
• Price to Book (P/B): 3.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: C$2.00 ▼(-16.67% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is held down primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by a stronger balance-sheet position (low leverage) and improving loss/cash-flow trends. Technicals are supportive with the stock above key moving averages, while valuation is difficult to support due to losses and no dividend yield.

Positive Factors

Low Leverage / Strong Equity Base

A very low debt load and positive equity position materially reduce refinancing and solvency risk for a cash-burning clinical biotech. This balance-sheet strength gives management flexibility to fund R&D or negotiate licensing deals without immediate pressure to dilute equity or take expensive debt.

Operational Streamlining & Regulatory Feedback

Management actions to close a lab and end non-core collaborations indicate active cost control and focus on core assets; positive FDA feedback on study design reduces regulatory uncertainty and can materially raise the probability of efficient trial execution and future partnering opportunities.

Improving Cash Burn Trend

A demonstrable reduction in operating cash outflow shows improving operational efficiency and extends runway given existing resources. While still negative, improving cash flow trends make future financing needs less acute and support sustained development activity over the coming months.

Negative Factors

No Revenue / Persistent Losses

Absence of product revenue means the company cannot self-fund R&D or operations; persistent losses imply continued dependency on external financing. Over the medium term, this elevates dilution and execution risk and constrains the company's ability to scale or absorb trial setbacks without partner support.

Negative Cash Generation & Funding Reliance

Sustained negative cash flows require recurring capital raises or deal-based financing, which can be dilutive or time-consuming. This structural reliance increases exposure to market access risk and may force suboptimal deal terms or project prioritization if capital markets tighten.

Clinical-stage Execution Risk / Limited Commercialization

As a clinical-stage company with no approved products, revenue outcomes are binary and long-dated. Success depends on trial results, regulatory approval, or partner deals; combined with limited internal commercial experience, this raises structural execution risk and makes long-term cash generation uncertain.

Helix BioPharma Business Overview & Revenue Model

Company Description

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Helix BioPharma’s ability to generate recurring revenue from product sales depends on successfully advancing drug candidates through clinical development and obtaining regulatory approval; publicly available, up-to-date detail on current, material commercial revenues from approved products: null. Typical monetization pathways for a company at this stage include (1) out-licensing or co-development deals in which a partner pays upfront fees, milestone payments tied to clinical/regulatory progress, and ongoing royalties on net sales if a product is commercialized; Helix BioPharma’s current, specific licensing/partnership arrangements and their financial terms: null. (2) If it retains rights and commercializes a product itself after approval, it would earn revenue from product sales (net of rebates/discounts) and potentially from distribution arrangements; evidence of an existing commercial product revenue stream: null. (3) The company may also receive non-dilutive funding such as grants or research credits, or generate other operating income, but specific, material amounts and sources for Helix BioPharma: null. In practice, for many clinical-stage biotech firms, a substantial portion of cash inflows can come from financing activities (equity or debt) rather than operating revenue; however, financing is not operating revenue and Helix BioPharma’s specific funding mix and material contributors: null.

Helix BioPharma Financial Statement Overview

Summary

Operating performance is very weak: no revenue, negative gross profit, and persistent net losses (TTM net loss ~4.9M). The balance sheet is a relative positive with modest leverage (TTM debt-to-equity ~0.02) and positive equity, but ongoing cash burn (TTM operating and free cash flow ~-4.2M) keeps funding risk elevated despite modest improvement versus 2024.

Income Statement

Across the period (including TTM (Trailing-Twelve-Months)), the company reports no revenue and persistent losses, with negative gross profit indicating ongoing operating costs without product sales. Losses remain sizeable (TTM net loss of ~4.9M), though the annual net loss improved versus 2024 (~9.3M), suggesting some cost containment. Overall profitability is still weak with no visible path to self-sustaining earnings in the reported figures.

Balance Sheet

Leverage is currently modest (TTM debt-to-equity ~0.02) with total debt (~0.35M) small relative to equity (~16.1M), which is a clear positive versus earlier years that showed negative equity (2021–2024) and, at times, high leverage (e.g., 2022). However, returns on equity are negative in the most recent periods due to ongoing net losses, and the historical swing from negative to positive equity highlights past balance-sheet stress and potential dilution/recapitalization risk.

Cash Flow

Cash generation remains negative, with TTM operating cash flow of about -4.2M and free cash flow also about -4.2M, implying continued cash burn to fund operations. Cash burn has improved versus 2024 (operating cash flow moved from about -5.2M to -4.2M), but operating cash flow still does not cover losses and the business remains reliant on external funding. Free cash flow largely tracks net loss, indicating limited non-cash offsets and no internally funded runway evident from these figures alone.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.00K	-10.00K	-14.00K	-13.00K	-12.00K	-173.00K
EBITDA	-4.62M	-5.21M	-9.38M	-6.31M	-6.03M	-9.46M
Net Income	-4.88M	-5.21M	-9.26M	-6.29M	-6.08M	-7.91M
Balance Sheet
Total Assets	19.07M	18.80M	1.49M	1.03M	3.73M	4.07M
Cash, Cash Equivalents and Short-Term Investments	498.00K	65.00K	1.08M	808.00K	3.25M	3.56M
Total Debt	352.00K	335.00K	0.00	0.00	2.47M	3.61M
Total Liabilities	3.00M	3.22M	1.58M	1.87M	3.41M	5.46M
Stockholders Equity	16.07M	15.59M	-90.00K	-844.00K	319.00K	-1.39M
Cash Flow
Free Cash Flow	-4.19M	-3.83M	-5.23M	-5.54M	-6.51M	-9.30M
Operating Cash Flow	-4.19M	-3.83M	-5.22M	-5.53M	-6.51M	-9.30M
Investing Cash Flow	9.00K	17.00K	-14.00K	-5.00K	0.00	2.02M
Financing Cash Flow	4.45M	2.80M	5.51M	3.09M	6.21M	6.56M

Helix BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HBP, the sentiment is Positive. The current price of 2.4 is above the 20-day moving average (MA) of 1.97, above the 50-day MA of 2.06, and above the 200-day MA of 1.77, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.90 is Neutral, neither overbought nor oversold. The STOCH value of 31.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HBP.

Helix BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HBP	52 Neutral	C$156.58M	-37.63	-66.34%	―	―	59.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	C$208.70M	-5.03	-89.10%	―	―	27.53%
MDNA	42 Neutral	C$59.11M	-4.40	-91.21%	―	―	54.74%
ARCH	41 Neutral	C$48.86M	-12.93	―	―	―	10.49%

Helix BioPharma Corporate Events

Helix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC London

Helix BioPharma unveiled new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference, highlighting a proprietary VHH-based nanobody with tumor-selective binding. The company said the data support development of next-generation ADCs designed to deliver potent payloads directly to cancer cells while sparing healthy tissue, reinforcing Helix’s positioning as an emerging player in CEACAM6-targeted oncology and potentially broadening treatment options for multiple hard-to-treat epithelial cancers.

Company scientists emphasized that CEACAM6 is highly expressed across a range of epithelial tumors and linked to poor outcomes, while being largely absent in healthy tissue. The presentation, which drew strong interest from industry peers at the high-profile ADC forum, builds on clinical signals from L-DOS47 in non-small cell lung cancer and may help attract further scientific collaboration and stakeholder attention to Helix’s growing ADC platform.

The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.

Helix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease Push

Helix BioPharma has extended metaShape Pharma’s exclusive research and option agreement for LEUMUNA in adipose tissue-related and metabolic diseases through December 31, 2028, preserving Helix’s rights to a potential high-value metabolic program while keeping its core strategic emphasis on oncology. The extension follows Helix’s acquisition of Laevoroc Immunology’s assets and is underpinned by encouraging metaShape-led preclinical data on MS 001 (LEUMUNA), which has shown improved weight-loss durability and metabolic efficiency in obese mice when used alongside GLP-1 therapies, potentially positioning both companies to benefit from growing demand for next-generation obesity and cardiometabolic treatments if the program advances successfully into clinical development.

The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.

Helix BioPharma Shareholders Back Board, Auditor and Share Consolidation Plan

Helix BioPharma Corp. reported that shareholders overwhelmingly approved all matters at its latest annual general and special meeting, with more than 81% of outstanding shares voted and all four director nominees re-elected by near-unanimous support. Investors also endorsed the reappointment of Clearhouse LLP as auditor and authorized a share consolidation of up to five existing shares for one new share at the board’s discretion, a move that could give the company greater flexibility in managing its capital structure and market positioning as it advances its oncology pipeline.

The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.